IN2014CN03214A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03214A
IN2014CN03214A IN3214CHN2014A IN2014CN03214A IN 2014CN03214 A IN2014CN03214 A IN 2014CN03214A IN 3214CHN2014 A IN3214CHN2014 A IN 3214CHN2014A IN 2014CN03214 A IN2014CN03214 A IN 2014CN03214A
Authority
IN
India
Prior art keywords
drug
fatty acid
acid ester
pharmaceutical compositions
increase
Prior art date
Application number
Inventor
Balasingam Radhakrishnan
Anuradha Vaidya
Navdeep Balkrishna Malkar
Karen Polowy
Kenneth Duke James Jr
Original Assignee
Seachaid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seachaid Pharmaceuticals Inc filed Critical Seachaid Pharmaceuticals Inc
Publication of IN2014CN03214A publication Critical patent/IN2014CN03214A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features pharmaceutical compositions including (i) a drug and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.
IN3214CHN2014 2011-10-21 2012-10-19 IN2014CN03214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549882P 2011-10-21 2011-10-21
PCT/US2012/061125 WO2013059664A1 (en) 2011-10-21 2012-10-19 Pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN03214A true IN2014CN03214A (en) 2015-07-03

Family

ID=48141411

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3214CHN2014 IN2014CN03214A (en) 2011-10-21 2012-10-19

Country Status (5)

Country Link
US (1) US9308263B2 (en)
EP (1) EP2775831A4 (en)
JP (2) JP6329486B2 (en)
IN (1) IN2014CN03214A (en)
WO (1) WO2013059664A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN03214A (en) * 2011-10-21 2015-07-03 Seachaid Pharmaceuticals Inc
CA2946832A1 (en) * 2013-04-25 2014-10-30 Seachaid Pharmaceuticals, Inc. Oral cefepime compositions and uses thereof
JPWO2021006267A1 (en) * 2019-07-08 2021-01-14
CN111053755B (en) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 Preparation method of high-permeability cefixime capsule preparation
CN111450057A (en) * 2020-06-03 2020-07-28 江苏中牧倍康药业有限公司 Cefquinome sulfate self-microemulsion and preparation method thereof
AU2021104067A4 (en) * 2021-07-12 2021-09-09 Pharmachem Australia Pty Ltd Oral antibiotic formulation
EP4493164A1 (en) 2022-03-17 2025-01-22 Bristol-Myers Squibb Company Pharmaceutical compositions comprising salts of salcaprozate and nicotinamide for improving oral bioavailability
CN120936346A (en) 2023-03-17 2025-11-11 百时美施贵宝公司 Pharmaceutical composition for improving oral bioavailability
CN120897744A (en) * 2023-04-06 2025-11-04 Ea制药株式会社 Self-emulsifying compositions containing sulfonamide derivatives and self-emulsifying drug delivery systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57146722A (en) * 1981-03-06 1982-09-10 Toyo Jozo Co Ltd Pharmaceutical preparation having improved absorption
US4537772A (en) 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (en) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
JP3440315B2 (en) * 1994-12-02 2003-08-25 小林製薬株式会社 Toilet cleaner composition
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2005004792A2 (en) 2003-06-24 2005-01-20 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1539117A4 (en) 2002-06-28 2005-12-14 Shire Lab Inc Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
EP1675548A4 (en) * 2003-09-25 2008-08-13 Activbiotics Inc Rifalazil formulations
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
CA2606386C (en) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
JP4343153B2 (en) 2005-05-12 2009-10-14 基博 中島 Method for producing antitumor composition
US20080145411A1 (en) 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
EA200970646A1 (en) * 2006-12-28 2009-12-30 Репрос Терапьютикс Инк. METHODS AND COMPOSITIONS FOR IMPROVING ANTI-PROGESTIN BIO-ACCESSIBILITY
US8362083B2 (en) * 2008-01-15 2013-01-29 C.B. Fleet Company Inc. Taste-masked docusate compositions
US9144606B2 (en) 2008-04-21 2015-09-29 Nanobio Corporation Nanoemulsion influenza vaccine
US9241519B2 (en) 2008-09-19 2016-01-26 Ironclad Performance Wear Corporation Glove for use in the oil and natural gas extraction industries
EP2338480A1 (en) * 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
IN2014CN03214A (en) * 2011-10-21 2015-07-03 Seachaid Pharmaceuticals Inc
CA2946832A1 (en) 2013-04-25 2014-10-30 Seachaid Pharmaceuticals, Inc. Oral cefepime compositions and uses thereof

Also Published As

Publication number Publication date
JP2018109037A (en) 2018-07-12
EP2775831A4 (en) 2015-08-12
EP2775831A1 (en) 2014-09-17
JP2014530875A (en) 2014-11-20
US20140329793A1 (en) 2014-11-06
WO2013059664A1 (en) 2013-04-25
JP6329486B2 (en) 2018-05-23
US9308263B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
IL254839B (en) Derivatives of piperidine-4- and -2-carboxylic acids, perhydroazepine-4-carboxylic acid and (piperidin-4-yl)-acetic acid and pharmaceutical compositions comprising them
MX358344B (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN INSOLUBLE ANTIPSYCHOTIC IN WATER AND SORES OF SORBITAN.
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
EA201290982A1 (en) PHARMACEUTICAL COMPOSITIONS, PREVENTING ABUSE
IL244858A0 (en) Molecular conjugates of fumarate and a fatty acid, pharmaceutical compositions comprising the same and uses thereof
CY1116698T1 (en) COMPOSITION CONTAINING SUPER-MICRONOMINATED PALMITOYL-ETHANOLAMIDE
MX388963B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
EP2827868A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS
BR112012005783A2 (en) nutritional compositions including exogenous vitamin K2
IN2014CN03290A (en)
MX340147B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
PL2701681T3 (en) Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
CL2010001587A1 (en) Process for preparing a concentrate of omega-3 fatty acid ethyl esters comprising over 80% by weight of said esters in cis configuration and their double bonds separated by a methylene unit.
ZA201400336B (en) Fatty acid composition and plant extract and pharmaceutical preparation and application thereof
EP2825057B8 (en) Oxidixable fatty acid composition delivery form
FR2981572B1 (en) PHARMACEUTICAL COMPOSITIONS OF URSODESOXYCHOLIC ACID
EP2928462A4 (en) METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID
CR20130318A (en) NEW BENZODIOXOL-PIPERAZINA COMPOUNDS
MX2015007678A (en) Transmucosal delivery of glatiramer acetate.
CO7111279A2 (en) Stable immediate-release oral pharmaceutical compositions containing prasugrel
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
SMT201600243B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANAKINRA WITHOUT CITRATE
UA105944C2 (en) Drug formulation with theobromine and decongestant for treatment of cough
EA032913B1 (en) Formulations of pyrimidinedione derivative compounds